(HealthDay News) — For cancer survivors, cognitive behavioral therapy for insomnia (CBT-I) with and without armodafinil is associated with decreases in insomnia severity and improvements in sleep quality, according to a study published online December 1 in the Journal of Clinical Oncology.

Joseph A. Roscoe, PhD, from the University of Rochester Medical Center in New York, and colleagues conducted a randomized trial involving 96 cancer survivors (mean age, 56 years) to assess insomnia treatment outcomes. The authors examined whether one or more of the seven-week intervention conditions (CBT-I, armodafinil, or both) produced greater clinical gains when compared with a placebo group.

The researchers observed significantly greater reductions in insomnia severity postintervention in both CBT-I plus armodafinil (P=0.001) and CBT-I plus placebo (P=0.010) groups, compared with placebo, after adjustment for baseline differences; the effect sizes were 1.31 and 1.02, respectively. Similar improvements in sleep quality were observed. Three months later, the gains on both measures persisted. There was no significant difference for CBT-I plus armodafinil or CBT-I plus placebo (P=0.421), and no significant difference was seen for armodafinil alone vs. placebo alone (P=0.584).

“CBT-I results in significant and durable improvements in insomnia and sleep quality,” the authors write.

The study was partially funded by Teva Pharmaceuticals, which provided study medication.

Full Text (subscription or payment may be required)